CNS Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 5
- Market Cap
- -
- Website
- http://www.cnspharma.com
- Introduction
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
- Conditions
- Glioblastoma Multiforme, Adult
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- CNS Pharmaceuticals, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT04762069
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸Southern California Permanente Medical Group, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
News
CNS Pharmaceuticals Presents Brain-Penetrating Taxane TPI 287 for Glioblastoma Treatment at 2025 Brain Tumor Summit
CNS Pharmaceuticals' Chief Medical Officer Sandra Silberman presented TPI 287, a brain-penetrating abeotaxane, at the 2025 Brain Tumor Biotech Summit on June 5, 2025.
CNS Pharmaceuticals Secures Orphan Drug Designation for TPI 287 in Brain Cancer Treatment
CNS Pharmaceuticals has successfully acquired Orphan Drug Designation from Cortice Biosciences for TPI 287, a novel abeotaxane with potential to cross the blood-brain barrier for treating brain tumors.
CNS Pharmaceuticals Reports Berubicin Trial Results in Glioblastoma Patients
CNS Pharmaceuticals released topline data from a Phase II/III clinical trial evaluating Berubicin versus Lomustine in 252 patients with recurrent Glioblastoma Multiforme.
Berubicin for Glioblastoma: CNS Pharmaceuticals Reports Comparable Efficacy to Standard Treatment with Improved Safety Profile
CNS Pharmaceuticals' Berubicin failed to demonstrate statistically significant superiority in overall survival compared to Lomustine in recurrent glioblastoma patients, but showed comparable clinical outcomes across multiple endpoints.
CNS Pharma's Berubicin Shows Promising Patient Retention in Recurrent GBM Trial
CNS Pharmaceuticals presented updated results from its pivotal study comparing Berubicin to Lomustine in recurrent glioblastoma (GBM) patients, showing comparable demographics between treatment arms.